Insider Buying: Vivani Medical (NASDAQ:VANI) Director Acquires $47,619.00 in Stock

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 48,100 shares of Vivani Medical stock in a transaction dated Friday, November 13th. The stock was acquired at an average cost of $0.99 per share, with a total value of $47,619.00. Following the completion of the acquisition, the director directly owned 36,960,836 shares in the company, valued at approximately $36,591,227.64. This trade represents a 0.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vivani Medical Price Performance

Vivani Medical stock opened at $1.01 on Monday. Vivani Medical, Inc. has a 1-year low of $0.80 and a 1-year high of $1.66. The company has a market cap of $91.11 million, a PE ratio of -3.16 and a beta of 2.51. The stock’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.24.

Vivani Medical (NASDAQ:VANI – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.

Analyst Upgrades and Downgrades

VANI has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.75.

View Our Latest Research Report on VANI

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

See Also

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.